Our Leadership

Alex Yang, J.D., LL.M. is the CEO/owner of Mstone Partners, which serves as the major shareholder of Polaryx. Since 2016, Alex has served in senior management and chair of board roles for a number of biopharmaceutical companies. Prior to the biotech incubation platform, Alex has over 25 years of experience in advising and executing fund formation, cross-border transactions, and a diverse pool of investment experiences in multiple industry sectors. He currently serves investment and risk committee member roles for various regional and country-focused private equity funds. Alex was formerly a managing partner at Kim & Chang and a partner at the Ernst & Young Hong Kong office leading regional financial services practice, including banking and capital markets, asset management, and insurance.

Alex formerly worked at the Morgan Stanley Hong Kong Office in the capacity of its Asia Private Equity and In-house Counsel, focused on buy-outs and grow-capital investments, real estate, special situation, and infrastructure transactions across Asia. He also worked at Coopers & Lybrand and Ernst & Young New York offices in their international tax and consulting divisions.

Alex graduated from New York University School of Law with both Juris Doctor (J.D.) and Master of Laws (LL.M.) degrees and a bar with the State of New York and received an undergraduate degree from Binghamton University in Economics.

Lisa Bollinger, M.D., is a board-certified pediatrician with over 30 years of experience in drug development with deep expertise in regulatory affairs and clinical safety. Prior to joining Polaryx, she founded Bollinger Regulatory Consulting (BRC), providing regulatory and clinical expertise to venture capital firms. Previously, she served as Vice President of Regulatory Affairs at Merck Sharp & Dohme, leading a team in general medicine, and held senior roles at Amgen for nearly 10 years. At the FDA, Lisa held leadership roles for over 12 years, including Associate Director at Office of New Drugs at CDER, where she oversaw the Pediatric and Maternal Health Staff (PMHS) and served as the Chair of the Pediatric Review Committee.

Lisa has also served as staff pediatrician to several hospitals within the National Health Service Corp (NHSC), United States Public Health Service (USPHS). She also served as Adjunct Professor of Pediatrics at the Uniformed Services University of the Health Sciences and is an author of numerous peer-reviewed publications. Lisa currently serves on the Board of Directors at Apogee Therapeutics.

Lisa holds a Doctor of Medicine (M.D.) degree from the Uniformed Services University of the Health Sciences and completed her residency in pediatrics at the University of California Davis Medical Center.

Eddy is a highly accomplished scientific professional, specializing in chemistry, manufacturing and controls (CMC) management with over 20 years of experience in commercial manufacturing, pharmaceutical development and regulatory approvals.

With an extensive background in both MNC and small startup environments, Eddy has a proven track record of success as a leader in technical R&D excellence, resulting in numerous peer-reviewed publications and several formulation patents.

Prior to joining Polaryx, Eddy served as Product Development Lead at Sanofi, where he played a critical role in pharmaceutical and non-pharmaceutical formulation and development across oral solids, liquids and injectables.

Eddy holds a Ph.D. in Applied Biological Sciences from Ghent University, A Master’s degree in Food Technology from K.U. Leuven and Ghent University through the inter-university program and a Bachelor’s degree in Plant Protection from Guangxi University.

Eddy also holds a Project Management Professional (PMP) certification from the Project Management Institute (PMI).

G. Michael Landis, CPA, is a highly accomplished financial executive who brings an over 25-year track record of public company expertise, capital market transactions, investor relations, and financial report. Immediately prior to joining Polaryx, Mike was Chief Financial Officer at Epygenix Therapeutics, a late-stage clinical biopharmaceutical company that was recently acquired in April 2024. Mike was also the Chief Financial Officer at Avisa Diagnostics Inc., a publicly traded medical device company. While there, he was responsible for strategic and tactical finance initiatives and was directly involved with investor relations and capital-raising activities. He also served as Principal Accounting Officer and Treasurer at Lannett Company Inc., a publicly traded pharmaceutical company, where he led acquisitions and related financing activities, and was a member of the executive team that successfully completed a $1.2 billion acquisition. Mike was actively involved in the Initial Public Offering (IPO) process in previous financial leadership roles at companies including Akrion Inc. and AlliedBarton Security Services, LLC. Mike has also worked at various other publicly traded companies after beginning his career within the Big Four public accounting firms.

Mike holds a Bachelor of Arts degree in accounting from Franklin & Marshall College in Lancaster, PA and is a Certified Public Accountant (CPA)

Andrew O has over twenty years of experience as an asset management and finance professional. Prior to serving as Polaryx’s Chief Investment Officer, Andrew held multiple positions within traditional fund management as well fundamentally-driven hedge fund investing roles at institutions such as Manulife Investment Management, Horizon Asset International, and FrontPoint Partners (Morgan Stanley). Andrew also worked at Goldman Sachs and the International Finance Corporation, the World Bank’s private investment arm.

Andrew graduated from the University of Pennsylvania and undertook Master’s level studies at Yonsei University’s Graduate School of International Studies.

Jay Vijayan, Ph.D., MBA is the Chief Scientific and Business Development Officer of Polaryx Therapeutics. Jay has worked at both public/private institutions as well as at eminent hospitals and Universities to assess, develop, and commercialize a wide range of technologies including therapeutics, diagnostics, and medical devices (from rare diseases to neurodegeneration, cancer, autoimmunity, and inflammation). He held several senior roles in technology commercialization in top academic institutions including as Director of Innovation at the Hospital for Special Surgery and Head of Technology Commercialization at Rush University Medical Center. Jay was Co-Founder and Director of Business Development and Scientific Affairs at Optimal Vision Corporation. In addition to executive roles, he has served as scientific advisor to several biotech companies and most recently as scientific advisor and board member of a publicly traded company (TLGY: NASDAQ).

Jay received his Ph.D. in Neuroscience from the City University of New York and completed his postdoctoral training at the University of Chicago where he conducted research on trafficking and regulation of key components of the gamma secretase in Alzheimer’s disease. Jay also holds a Master of Business Administration, Entrepreneurship from the University of Illinois in Chicago.

Minsu Kang, Ph.D., is Polaryx’s Director of Regulatory and Clinical Affairs. With over 10 years in CNS development, Minsu has extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative diseases. Prior to joining Polaryx, he served as Clinical Science Lead at Karuna Therapeutics (acquired by Bristol Myers Squibb), overseeing five global Phase 3 trials in Alzheimer’s disease from IND to End-of-Phase 2. Minsu was also previously Senior Medical Science Liaison at Biogen, where he gathered insights from physicians and key opinion leaders on clinical practices and unmet needs in neurology. With a strong background in multinational corporations and startups, he has demonstrated expertise in protocol development, regulatory interactions, and clinical trial execution, and is also the author of multiple peer-reviewed publications.

Minsu holds a Ph.D. in Cell Biology and Anatomy from the University of Illinois, Chicago and a B.S. in Neuroscience from the University of Illinois, Urbana-Champaign.